Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues.

Abstract

The integration of new genetic technologies into clinical practice holds great promise for the personalization of medical care, particularly the use of large-scale DNA sequencing for genome-wide genetic testing. However, these technologies also yield unprecedented amounts of information whose clinical implications are not fully understood, and we are still developing technical standards for measuring sequence accuracy. These technical and clinical challenges raise ethical issues that are similar to but qualitatively different from those that we are accustomed to dealing with for traditional medical genetics. The sheer amount of information afforded by genome sequencing requires rethinking of how to implement core ethical principles including, but not limited to: informed consent, privacy and data ownership and sharing, technology regulation, issues of access, particularly as new technology is integrated into clinical practice, and issues of potential stigma and impact on perceptions of disability. In this article, we will review the issues of informed consent, privacy, data ownership and technology regulation as they relate to the emerging field of personalized medicine and genomics.

02040201520162017
Citations per Year

Citation Velocity: 14

Averaging 14 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Ormond2014TranslatingPM, title={Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues.}, author={Kelly E. Ormond and Mildred K. Cho}, journal={Personalized medicine}, year={2014}, volume={11 2}, pages={211-222} }